SCHEMBL833121

SCHEMBL833121

O=C(O)C1(Br)C=CC=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5297786 0.72
SCHEMBL25352284 0.71
SCHEMBL1667413 0.71
SCHEMBL27550891 0.67
SCHEMBL2227258 0.67
SCHEMBL2955235 0.67
SCHEMBL29110050 0.67
SCHEMBL7325933 0.66
SCHEMBL30927993 0.64
SCHEMBL1303902 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762383-B1 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF US HEALTH (US) 2023-12-06 EP disclosed
CN-117088865-A 3CLpro protease inhibitor related substance and preparation method thereof 齐鲁制药有限公司 2023-11-21 CN disclosed
US-20210040074-A1 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-02-11 US disclosed
EP-3762383-A1 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2021-01-13 EP disclosed
US-10435398-B2 Oxazole orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2019-10-08 US disclosed
WO-2019173437-A1 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-09-12 WO disclosed
US-10150751-B2 Pyrrolidine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-12-11 US disclosed
US-10011595-B2 Ethyldiamine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-07-03 US disclosed
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-9920038-B2 Methyl oxazole orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-03-20 US disclosed
US-20090099181-A1 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. 2009-04-16 US disclosed
WO-2008061236-A2 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2008-05-22 WO disclosed
EP-0399818-B1 Diarylstyrylquinoline diacids MERCK FROSST CANADA INC (CA) 1995-08-16 EP disclosed
US-5166349-A CHIRAL ORGANOIRON COMPLEXES AND USE FOR ASSYMETRIC REDUCTION THE BRITISH PETROLEUM COMPANY, P.L.C. (GB) 1992-11-24 US disclosed
EP-0255075-B1 2-(ACYLTHIO)METHYL DIHYDROPYRIDINES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1992-09-30 EP disclosed
WO-1991006550-A1 CHIRAL ORGANOMETALLIC COMPLEXES AND USES THEREOF THE BRITISH PETROLEUM COMPANY PLC (GB) 1991-05-16 WO disclosed
EP-0426474-A1 Chiral organometallic complexes and uses thereof The British Petroleum Company p.l.c. (GB) 1991-05-08 EP disclosed
EP-0399818-A1 Diarylstyrylquinoline diacids MERCK FROSST CANADA INC. (CA) 1990-11-28 EP disclosed
US-4935433-A 2-(acylthio)methyl dihydropyridines, and pharmaceutical compositions containing them BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) 1990-06-19 US disclosed
EP-0255075-A1 2-(acylthio)methyl dihydropyridines, a process for their preparation and pharmaceutical compositions containing them BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1988-02-03 EP disclosed